Stage 2

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Monday, March 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

Full Schedule Released for Hong Kong Web3 Festival 2024

Retrieved on: 
Thursday, March 28, 2024
Tsinghua University, Festival, Exchange-traded product, Fidelity International, Associate, CME Group, Blockchain, Digital asset, Magic, AI, Senior, AWS, Convention center, Stage 2, Entrepreneurship, Associate professor, Open, Cryptocurrency

HONG KONG, March 28, 2024 /PRNewswire/ -- Following the success of its record-breaking 2023 event, HK Web3 Festival is returning for its second edition from 6 to 9, April at Hall3FG, Hong Kong Convention and Exhibition Centre.

Key Points: 
  • HONG KONG, March 28, 2024 /PRNewswire/ -- Following the success of its record-breaking 2023 event, HK Web3 Festival is returning for its second edition from 6 to 9, April at Hall3FG, Hong Kong Convention and Exhibition Centre.
  • Hosted by Wanxiang Blockchain Labs and HashKey Group, the Festival will convene over 160 game-changing projects, 100 media and 300+ notable speakers to exchange up-to-date knowledge, experiences, and views that are expected to shape the narrative around Web3 and blockchain.
  • With the event taking place in the innovation-rich city of Hong Kong, the Web3 Festival 2024 converges East and West ideologies.
  • It sets four regular conference areas and an open stage, providing an avenue for eclectic discussions around Web3, idol performance, Web3 professional esports tournament, and more!

Full Schedule Released for Hong Kong Web3 Festival 2024

Retrieved on: 
Thursday, March 28, 2024
Tsinghua University, Festival, Exchange-traded product, Fidelity International, Associate, CME Group, Blockchain, Digital asset, Magic, AI, Senior, AWS, Convention center, Stage 2, Entrepreneurship, Associate professor, Open, Cryptocurrency

HONG KONG, March 28, 2024 /PRNewswire/ -- Following the success of its record-breaking 2023 event, HK Web3 Festival is returning for its second edition from 6 to 9, April at Hall3FG, Hong Kong Convention and Exhibition Centre.

Key Points: 
  • HONG KONG, March 28, 2024 /PRNewswire/ -- Following the success of its record-breaking 2023 event, HK Web3 Festival is returning for its second edition from 6 to 9, April at Hall3FG, Hong Kong Convention and Exhibition Centre.
  • Hosted by Wanxiang Blockchain Labs and HashKey Group, the Festival will convene over 160 game-changing projects, 100 media and 300+ notable speakers to exchange up-to-date knowledge, experiences, and views that are expected to shape the narrative around Web3 and blockchain.
  • With the event taking place in the innovation-rich city of Hong Kong, the Web3 Festival 2024 converges East and West ideologies.
  • It sets four regular conference areas and an open stage, providing an avenue for eclectic discussions around Web3, idol performance, Web3 professional esports tournament, and more!

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Retrieved on: 
Thursday, March 28, 2024
OHE, Week, Cirrhosis, Patient, Mitt, NDA, MOA, File, Stage 2, SMI, Recurrence, FDA

SALT LAKE CITY, March 28, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148.

Key Points: 
  • SALT LAKE CITY, March 28, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148.
  • LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action (MOA).
  • This Phase 2 proof of concept study was a randomized placebo-controlled study in sarcopenic male patients with cirrhosis on the liver transplant waitlist.
  • During Stage 2, 8 participants who were on placebo in Stage 1 converted to LPCN 1148, and 11 participants who started the study on LPCN 1148 continued treatment with LPCN 1148.

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, Conference, Pneumonia, CRAC, Disease, Incidence, GFR, AKI, Patient, Physiology, COVID-19, Renal artery, Biomarker, Hemofiltration, T helper 17 cell, Mortality, Indiana University, Cell biology, Glomerular filtration rate, Respiratory failure, Doctor of Philosophy, Acute kidney injury, Ischemia, Kidney, Poster, Stage 2, Blood, Animal, Hospice and palliative medicine, Pharmaceutical industry

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points: 
  • In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
  • We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
  • The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
  • These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

Retrieved on: 
Thursday, February 29, 2024
SAN, FDA, Food, Stage 2, PTCL, Epstein–Barr virus, Valganciclovir, EBV, Therapy, Patient, Peripheral T-cell lymphoma, Pharmaceutical industry

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its lead development program, Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, has completed Stage 2 enrollment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort of the NAVAL-1 trial.

Key Points: 
  • “The completion of Stage 2 enrollment of the PTCL cohort in NAVAL-1 is a major milestone for the Nana-val clinical development program.
  • We would like to acknowledge the dedication of our study execution team and the commitment of our investigators for this achievement.
  • Present Stage 1 + Stage 2 data (n=21) from the R/R EBV+ PTCL cohort in patients treated with Nana-val in the third quarter of 2024.
  • Engage with the U.S. Food and Drug Administration (FDA) in mid-2024, to align on requirements for accelerated approval.

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024
EMANATE, New Drug Application, Investment, Obesity, BMI, Webcast, Initiate, BBS, Stage 2, Hyperpigmentation, Documentation, Polyphagia, European, GAAP, European Medicines Agency, PCSK1, Type, Type 2, G&A, LG Chem, BV, Completeness, Shanda, Bardet–Biedl syndrome, Clinical trial, LEPR, Medicaid, IND, Prescription, Research, Hunger, Acquisition, Quarter, EMA, MC4R, FDA, Prevalence, PMDA, Patient, POMC, Body mass index, Pharmaceutical industry

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Unleash live Joins AAM CRC in Advancing Australia's Aerospace and Aviation Industry

Retrieved on: 
Friday, March 8, 2024
Environment, Technology, Air, Transport, Other Technology, Aerospace, Drones, Manufacturing, Sustainability, Partnership, Aviation, System, Stage 2, Atmosphere, Air travel, AAM, CRC, Multimedia, Research, University

Unleash live is excited to announce its participation in the Advanced Air Mobility Cooperative Research Centre (AAM CRC), a groundbreaking initiative aimed at transforming Australia's aerospace and aviation sector.

Key Points: 
  • Unleash live is excited to announce its participation in the Advanced Air Mobility Cooperative Research Centre (AAM CRC), a groundbreaking initiative aimed at transforming Australia's aerospace and aviation sector.
  • Through interdisciplinary collaboration, the CRC aims to propel Australia towards a clean, sustainable and globally competitive aerospace future.
  • As we move into Stage 2, Unleash live remains committed to supporting Australia's leadership in advanced autonomous air mobility.
  • Unleash live is proud to support this effort and together, let's lead the way in advanced air mobility."

Dragos OT Cybersecurity “Year in Review” Reports Rise in Geopolitically Driven Attacks, Ransomware, and Threat Groups

Retrieved on: 
Tuesday, February 20, 2024
Software, Technology, Data Management, Security, Internet, Necessity and sufficiency, Research, Commonwealth, POC, Aviation, Stage 2, Government, Rockwell Automation, Independence, Hacktivism, OT, Organization, ICS, Telecommunications, Denial-of-service attack, Environment, Inc., Separate, Oracle Applications, Arms industry

Dragos Inc., the global leader in cybersecurity for operational technology (OT) environments, today released its sixth annual Dragos OT Cybersecurity Year in Review report, the most comprehensive report on cyber threats facing industrial organizations.

Key Points: 
  • Dragos Inc., the global leader in cybersecurity for operational technology (OT) environments, today released its sixth annual Dragos OT Cybersecurity Year in Review report, the most comprehensive report on cyber threats facing industrial organizations.
  • “OT cyber threats reached a tipping point in 2023,” said Robert M. Lee, co-founder and CEO of Dragos.
  • With these additions, Dragos analysts now track 21 Threat Groups worldwide that have been observed as being engaged in OT operations in 2023.
  • The 2023 Dragos OT Cybersecurity Year in Review is an annual overview and analysis of OT-focused global threat activities, vulnerabilities, and industry insights and trends.

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Retrieved on: 
Thursday, January 25, 2024
Patient, ATP7B, Stage 2, Data, Safety, Wilson's disease, Pinnacle, Week, Physician, Pharmaceutical industry

NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been dosed with UX701 across the three dose-escalation cohorts in Stage 1 of its pivotal Phase 1/2/3 Cyprus2+ study. The company's investigational AAV9 gene therapy is designed to deliver stable expression of the ATP7B copper transporter following a single intravenous infusion, with the goal of normalizing copper metabolism in patients with Wilson disease.

Key Points: 
  • Four of five patients enrolled in Cohort 1 had started tapering standard-of-care treatment, including two that came completely off of chelators and/or zinc therapy.
  • This study evaluating UX701 for the potential treatment of Wilson disease is designed with three stages.
  • In Stage 2, a new cohort of patients will be randomized 2:1 to receive the selected dose of UX701 or placebo.
  • After the initial 52-week study period, all patients will have long-term follow up in Stage 3.